• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

POC study demonstrates feasibility of using Nanoform’s nanoforming technology for potential intranasal formulation of CDNF

Nanoform Finland and Herantis Pharma say that they have successfully demonstrated the feasibility of using Nanoform’s nanoparticle technology for a potential intranasal formulation of Herantis’s cerebral dopamine neurotrophic factor (CDNF) for the treatment of Parkinson’s disease, with the protein remaining stable and active following processing.

The two companies announced their plans for the proof of concept study in February 2021. According to the latest announcement, Nanoform and Herantis will now conduct a proof of process study to optimize the CDNF particles for nasal delivery.

Nanoform Chief Commercial Officer Christian Jones said, “We are excited with these initial results that show nanoforming is effective with Herantis’ rhCDNF program. This POC study with Herantis Pharma’s rhCDNF further validates the wide applicability of Nanoform’s technologies to a diverse range of molecules. We look forward to now moving into a POP study and further nanoforming activities as rhCDNF continues its development.”

Herantis Pharma CEO Craig Cook commented, “This was a key milestone to achieve as part of our broader intranasal administration project for rhCDNF, one of only a few clinical stage assets focused on disease modification of Parkinson’s disease.  The ability to nanoform the rhCDNF molecule improves the chances of success for intranasal administration and creates additional possibilities to impact the lives of patients. We very much look forward to progressing the work with Nanoform.”

Read the Nanoform press release.

Share

published on September 9, 2021

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews